Prevalence and risk factors of steatosis after liver transplantation and patient outcomes

Liver Transplantation

Volumn 22, Issue 5, 2016, Pages 644-655

  Hejlova, Irena ^a   Honsova, Eva ^a   Sticova, Eva ^a   Lanska, Vera ^a   Hucl, Tomas ^a   Spicak, Julius ^a   Jirsa, Milan ^a   Trunecka, Pavel ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AZATHIOPRINE; CREATININE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; TACROLIMUS; MYCOPHENOLIC ACID; TRIACYLGLYCEROL;

ADULT; ALCOHOL CONSUMPTION; ALCOHOL LIVER CIRRHOSIS; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE COURSE; FEMALE; GRAFT RECIPIENT; HUMAN; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL TIME; TRIACYLGLYCEROL BLOOD LEVEL; BIOPSY; BLOOD; DRINKING BEHAVIOR; LIVER CIRRHOSIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; TIME FACTOR; TREATMENT OUTCOME;

ADULT; ALCOHOL DRINKING; ALKALINE PHOSPHATASE; BIOPSY; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; NON-ALCOHOLIC FATTY LIVER DISEASE; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 84963705832     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.24393     Document Type: Article

References (30)

1. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Srishord M,. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524-530.
2. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P,. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
3. Söderberg C, Stäl P, Askling J, Glaumann H, Lindberg G, Marmur J, Hultcrantz R,. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010; 51: 595-602.
4. Calori G, Lattuada G, Ragogna F, Garancini MP, Crosignani P, Villa M, et al., Fatty liver index and mortality: the Cremona study in the 15th year of follow-up. Hepatology 2011; 54: 145-152.
5. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S,. Prevalence of and risk factors for nonalcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005; 42: 44-52.
6. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, Cohen JC, et al., Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004; 40: 1387-1395.
7. Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, et al., Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013; 178: 38-45.
8. Yan J, Xie W, Ou WN, Zhao H, Wang SY, Wang JH, et al., Epidemiological survey and risk factor analysis of fatty liver disease of adult residents, Beijing, China. J Gastroenterol Hepatol 2013; 28: 1654-1659.
9. Powell EE, Jonsson JR, Clouston AD,. Steatosis: co-factor in other liver diseases. Hepatology 2005; 42: 5-13.
10. Sookoian S, Pirola CJ,. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011; 53: 1883-1894.
11. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, et al., Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am J Gastroenterol 2010; 105: 613-620.
12. Lim LG, Cheng CL, Wee A, Lim SG, Lee YM, Sutedja DS, et al., Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int 2007; 27: 76-80.
13. Seo S, Maganti K, Khehra M, Ramsamooj R, Tsodikov A, Bowlus C, et al., De novo nonalcoholic fatty liver disease after liver transplantation. Liver Transpl 2007; 13: 844-847.
14. Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J,. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl 2009; 15: 1843-1851.
15. Dureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A,. NAFLD recurrence in liver transplant recipients. Transplantation 2011; 91: 684-689.
16. Finkenstedt A, Auer C, Glodny B, Posch U, Steitzer H, Lanzer G, et al., Patatin-like phospholipase domain-containing protein 3 rs738409-G in recipients of liver transplants is a risk factor for graft steatosis. Clin Gastroenterol Hepatol 2013; 11: 1667-1672.
17. Dunn W, O'Neil M, Zhao J, Wu CH, Roberts B, Chakraborty S, et al., Donor PNPLA3 rs738409 genotype affects fibrosis progression in liver transplantation for hepatitis C. Hepatology 2014; 59: 453-460.
18. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al.,; for Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
19. Richards J, Gunson B, Johnson J, Neuberger J,. Weight gain and obesity after liver transplantation. Transpl Int 2005; 18: 461-466.
20. Loria P, Marchesini G, Nascimbeni F, Ballestri S, Maurantonio M, Carubbi F, et al., Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. Atherosclerosis 2014; 232: 99-109.
21. Gabbi C, Bertolotti M, Anzivino C, Macchioni D, Del Puppo M, Ricchi M, et al., Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease. Dig Liver Dis 2012; 44: 1018-1026.
22. Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, et al.,; for Dutch PBC Study Group. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009; 136: 1281-1287.
23. Lindström L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A,. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 2013; 11: 841-846.
24. Sorrentino P, Terracciano L, D'Angelo S, Ferbo U, Bracigliano A, Tarantino L, et al., Oxidative stress and steatosis are cofactors of liver injury in primary biliary cirrhosis. J Gastroenterol 2010; 45: 1053-1062.
25. Harita N, Hayashi T, Sato KK, Nakamura Y, Yoneda T, Endo G, Kambe H,. Lower serum creatinine is a new risk factor of type 2 diabetes: the Kansai healthcare study. Diabetes Care 2009; 32: 424-426.
26. Maksimovic-Ivanic D, Trajkovic V, Miljkovic DJ, Mostarica Stojkovic M, Stosic-Grujicic S,. Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil. Clin Exp Immunol 2002; 129: 214-223.
27. Hao L, Chan SM, Lafferty KJ,. Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann N Y Acad Sci 1993; 696: 328-332.
28. Ugrasbul F, Moore WV, Tong PY, Kover KL,. Prevention of diabetes: effect of mycophenolate mofetil and anti-CD25 on onset of diabetes in the DRBB rat. Pediatr Diabetes 2008; 9: 596-601.
29. Neuschwander-Tetri BA, Caldwell SH,. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
30. Evans HM, Kelly DA, McKiernan PJ, Hübscher S,. Progressive histological damage in liver allografts following pediatric liver transplantation. Hepatology 2006; 43: 1109-1117.